Medlab Clinical
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11-13 Lord Street Units 5 and 6, Botany,...Phone Number
+61 281880311Website
www.medlab.coRevenue
<$5 MillionStock Symbol
MDCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Medlab Clinical
Medlab Clinical Ltd (ASX:MDC) is pioneering the development and commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis may be equally effective in non-cancer neuropathic pain. NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory. NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.Explore more
Medlab Clinical Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Medlab Clinical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Medlab Clinical launches new products
Check if Medlab Clinical has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Medlab Clinical has new funding data
Click to see if Medlab Clinical had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Medlab Clinical is spiking on competitors!
Medlab Clinical, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Medlab Clinical
Earning: See what the market has to say on Medlab Clinical recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Medlab Clinical
Compare insights from companies similar to Medlab Clinical, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Medlab Clinical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Medlab Clinical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Medlab Clinical.
Medlab Clinical financials insights
Gather financial insights about Medlab Clinical, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$3.7M
Medlab Clinical Tech Stack
A closer look at the technologies used by Medlab Clinical
Medlab Clinical News & Media
Medlab Clinical Full Year 2022 Earnings: Beats Expectations
Medlab Clinical ( ASX:MDC ) Full Year 2022 Results Key Financial Results Revenue: AU$1.54m (up 110% from FY 2021). Net...Medlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in
NSW Government grant received on 23rd December 2021 to develop a “no-jab” vaccine solutionMedlab collaborates with UNSW and MQ University (two leading global academic and R&D institutions)This NanoCelle® non-invasive nasalMedlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in collaboration with University of NSW (UNSW) and Macquarie University (MQ) to fight COVID-19 future potential epidemics
SYDNEY, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Medlab Clinical Ltd (ASX:MDC) is pleased to announce in collaboration with Prof Pall Thordarson (Director of the UNSW RNA Institute, UNSW) and Prof Daniela Traini (NHMRC Investigator, Biomedical Sciences, Macquarie University and The Woolcock Institute of Medical Research) received a NSW Government grant to develop a Proof-of-Concept NanoCelle® Nasal RNA vaccine as part of Australia’s need to develop innovative infrastructure and manufacturing for the onNanocelle® Patent Granted in Usa
Medlab receives Granted Patent Protection for NanoCelle® in the USA by US Patent & Trademark Office (USPTO)
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Medlab Clinical
Sign Up For FreeTo access detailed company insights
Medlab Clinical Ltd (ASX:MDC) is pioneering the development and commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of... Read More
